Shield Therapeutics (STX) detailed a series of achievements in its FY19 business update. The highlights included a 67% increase in sales volumes in European markets and, notably, FDA approval of Feraccru (Accrufer) with the broadest possible label to treat iron deficiency with or without anaemia. I
03 Feb 2020
Shield Therapeutics: Achieving significant milestones
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Shield Therapeutics: Achieving significant milestones
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
03 Feb 2020 -
Author:
Emma Ulker -
Pages:
5
Shield Therapeutics (STX) detailed a series of achievements in its FY19 business update. The highlights included a 67% increase in sales volumes in European markets and, notably, FDA approval of Feraccru (Accrufer) with the broadest possible label to treat iron deficiency with or without anaemia. I